Advaxis (NASDAQ:ADXS) Trading Up 11.3%

Advaxis, Inc. (NASDAQ:ADXS) shares were up 11.3% during mid-day trading on Wednesday . The company traded as high as $0.36 and last traded at $0.28, approximately 28,310,008 shares changed hands during trading. An increase of 2,660% from the average daily volume of 1,025,552 shares. The stock had previously closed at $0.25.

A number of equities analysts recently issued reports on ADXS shares. HC Wainwright restated a “neutral” rating on shares of Advaxis in a report on Wednesday, June 12th. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Advaxis from a “sell” rating to a “hold” rating in a report on Friday, August 9th.

The firm has a market capitalization of $5.05 million, a PE ratio of -0.01 and a beta of 3.21. The company has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $1.85.



Hedge funds have recently modified their holdings of the business. Deutsche Bank AG lifted its holdings in shares of Advaxis by 5,970.3% in the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Advaxis by 71.1% in the 2nd quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after buying an additional 95,607 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Advaxis by 143.7% in the 2nd quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after buying an additional 295,444 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Advaxis by 53,633.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after buying an additional 50,952 shares during the period. Institutional investors and hedge funds own 7.32% of the company’s stock.

Advaxis Company Profile (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Is the QQQ ETF safe?

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.